Tag: Skyepharma
-
Skyepharma launches Flutiform in France for asthma – The Pharma Letter
Skyepharma launches Flutiform in France for asthmaThe Pharma LetterUK drug delivery specialist Skyepharma (LSE: SKP) has received regulatory approval and agreement on pricing reimbursement for asthma treatment Flutiform in France. Skyepharma's licensee Mundipharma, responsible for the development and …Skyepharma Jumps As It Launches Flutiform in FranceLondon South Eastall 2 news articles » View full post on asthma…
-
SkyePharma launches asthma treatment in Germany – Stock Market Wire
SkyePharma launches asthma treatment in GermanyStock Market Wireflutiform® was approved for the treatment of asthma maintenance therapy in Germany by its regulatory authority, Bundesinstitut für Arzneimittel und Medizinprodukte (BfARM), in July. Following the launch offlutiform® in Germany, a milestone of €4.0m is …SkyePharma Launches Flutiform In Germany – Quick FactsNASDAQall 4 news articles » View full…
-
SkyePharma soars on asthma drug approval – Telegraph.co.uk
SkyePharma soars on asthma drug approvalTelegraph.co.ukBy Rachel Cooper, City Reporter SkyePharma has been hurt by concerns over its asthma therapy, Flutiform, with the share price taking a tumble just before Christmas as traders learnt of another delay to its European approval.SkyePharma asthma drug wins European backingReuters UKSkyePharma's asthma drug wins European backingLondon South Eastall 5…
-
SkyePharma asthma drug wins European backing – Reuters UK
SkyePharma asthma drug wins European backingReuters UKBy Paul Sandle | LONDON (Reuters) – SkyePharma said on Friday its lead product, asthma therapy Flutiform, had been recommended for approval by European regulators, doubling the value of the group's shares. Flutiform was referred to the European …SkyePharma's asthma drug wins European backingLondon South Eastall 4 news articles »…
-
MARKET REPORT: Skyepharma in a jam over asthma drug – This is Money
This is Money MARKET REPORT: Skyepharma in a jam over asthma drugThis is Money… was run by its controversial founder Ian Gowrie Smith, who then had a history of over-promising and under-delivering, the City was up in arms after he announced a shock deeply-discounted £35m rights issue to develop Flutiform, its asthma treatment. …SkyePharma's Asthma…
-
Skyepharma banking on European approval for Flutiform – Stock Market Wire
Skyepharma banking on European approval for FlutiformStock Market WireThe group said it was counting on European approval of asthma treatment Flutiform and launch in the second half of 2011. Revenue was up 4% to £58.1m from £55.9m, in line with management expectations. The rise was primarily due to a substantial increase …SkyePharma Moves To 2010…
-
SkyePharma Moves To 2010 Pretax Profit, Sees Cash Outflows – Wall Street Journal
SkyePharma Moves To 2010 Pretax Profit, Sees Cash OutflowsWall Street JournalLN) Wednesday said it swung to a 2010 pretax profit, but it expects substantial cash outflows in 2011 relating to the planned European launch of its flagship asthma treatment Flutiform in the second half of the year. The company also said it expects …and more »…
-
AZ withdraws asthma drug, bad news for SkyePharma – Pharma Times
AZ withdraws asthma drug, bad news for SkyePharmaPharma TimesAstraZeneca is to discontinue production of the pressurised metered dose inhaler version of its asthma treatment Pulmicort as a result of manufacturing problems. The Anglo-Swedish drugmaker says the decision has been taken to pull Pulmicort pMDI …Astra pulls asthma product, hitting SkyePharmaReutersAstraZeneca ends production of Pulmicort inhaler,…
-
Astra pulls asthma product, hitting SkyePharma – Reuters
Astra pulls asthma product, hitting SkyePharmaReutersL) is ending production of the pressurised metered dose inhaler version of its asthma drug Pulmicort, due to technical problems, in a move that will hit its technology partner SkyePharma (SKP.L). SkyePharma developed the formulation for the medicine …and more » View full post on asthma – Google News
-
Skyepharma Confirms 2010 Guidance, Sees Fall In 2011 Revenues – Wall Street Journal
Skyepharma Confirms 2010 Guidance, Sees Fall In 2011 RevenuesWall Street JournalIn August, SkyePharma PLC's partner Abbott Laboratories (ABT) pulled out of development of the asthma treatment due to the lack of progress.and more » View full post on asthma – Google News